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Abstract
Background: The overexpression of the chemokine receptor 4 (CXCR4) in different epithelial, mesenchymal, and
hematopoietic cancers makes CXCR4 an attractive diagnostic and therapeutic target. However, targeting the CXCR4
receptor with small cyclic pentapeptide-based radiopharmaceuticals remains challenging because minor structural
modifications within the ligand-linker-chelate structure often significantly affect the receptor affinity. Based on the
excellent in vivo properties of CXCR4-directed pentapeptide [68Ga]pentixafor (cyclo(-D-Tyr-N-Me-D-Orn(AMB-DOTA)-
L-Arg-L-2-Nal-Gly-)), this study aims to broaden the spectrum of applicable (radio)metal-labeled pentixafor analogs.
Methods: Cyclic pentapeptides, based on the pentixafor scaffold, were synthesized by a combined solid- and solution-
phase peptide synthesis. The CXCR4 receptor affinities of the cold reference compounds were determined in
competitive binding assays using CXCR4-expressing Jurkat T - cell leukemia cells and [125I]FC131 as the radioligand.
Results: Metalated pentixafor derivatives with cyclic and acyclic chelators were synthesized by solid-phase peptide
synthesis and evaluated in vitro. The resulting CXCR4 affinities (IC50) were highly dependent on the chelator
and metal used. Two pentapeptides, Ga-NOTA and Bi-DOTA conjugates, offer an improved affinity compared to
[68Ga]pentixafor.
Conclusions: Based on the pentapeptide [68Ga]pentixafor, a broad range of metal-labeled analogs were
investigated. The affinities of the new compounds were found to be strongly dependent on both the chelator
and the metal used. Bi-labeled pentixafor showed high receptor affinity and seems to be a promising ligand for
further preclinical evaluation and future α-emitter-based endoradiotherapy.
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Background
The chemokine receptor 4 (CXCR4) and its sole known
natural ligand stromal cell derived factor-1 (SDF-1,
CXCL12) are physiologically involved in leukocyte re-
cruitment, homing, and retention of hematopoietic stem
and progenitor cells [1, 2]. CXCR4 also holds a substantial
role in various pathological conditions and represents a
highly attractive therapeutic target. Overexpression of
CXCR4 has been linked to cancer proliferation, cell migra-
tion, and tissue-specific homing of cancer cells as well as
resistance to conventional and targeted therapies [3–5].
After the identification of CXCR4 as a co-receptor for the
entry of the HIV virus [6], great efforts have been made to-
wards the development of CXCR4 antagonists. Recently,
our group has developed [68Ga]pentixafor (cyclo(-D-Tyr-N-
Me-D-Orn(aminomethylbenzoyl (AMB)-DOTA)-L-Arg-L-
2-Nal-Gly-), [68Ga]1, Fig. 1), a cyclic pentapeptide with
5 nM affinity and high selectivity towards hCXCR4 [7, 8].
[68Ga]pentixafor exhibits high uptake and long retention
in CXCR4-expressing tissues (6.16 % ± 1.16 % ID/g, 1 h
post-injection (p.i.) and 4.63 % ± 1.54 %, 2 h p.i. in OH1
human small cell lung cancer tumor-bearing mice) and is
rapidly cleared from non-target tissue (1.08 % ± 0.27 % in
the blood, 1 h p.i.) and renally excreted [7]; the corre-
sponding tumor-to-blood and tumor-to-muscle ratios* Correspondence: a.poschenrieder@tum.de1Pharmaceutical Radiochemistry, Technical University Munich,
Walther-Meißner-Str.3, 85748 Garching, Germany
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are substantially higher than those compared to other
peptidic CXCR4 imaging agents [8]. First, studies in
patients suffering from lymphoproliferative diseases
[9, 10] demonstrated its excellent properties, including
a favorable dosimetry for CXCR4-receptor mapping by
means of positron emission tomography (PET) [11].
Based on the success of [68Ga]pentixafor, this study
aims to broaden the potential spectrum of radiometal-
labeled CXCR4 ligands, both for imaging and therapy,
by development and in vitro evaluation of a range of tracers
labeled with alternative radionuclides, such as 111In3+ (for
single photon emission computed tomography (SPECT));
18F− and 89Zr4+ (for PET); or 90Y3+, 177Lu3+, and 213Bi3+ (for
endoradiotherapy).
However, the experiences gained during the develop-
ment of pentixafor have shown that, compared with
[68Ga]pentixafor, unlabeled pentixafor and other radio-
metalated pentixafor derivatives exhibit significantly
lower CXCR4 receptor affinities. Thus, in contrast to
other peptides, such as somatostatin receptor (SSTR),
gastrin-releasing peptide receptor (GRPR), or αvβ3 bind-
ing peptides, the affinity of [68Ga]pentixafor towards
CXCR4 is determined by the entire ligand-spacer-
chelator-radiometal construct. Consequently, a more or
less independent “bioactive substructure” or “pharmaco-
phor” (e.g., the pentapeptide core A depicted in Fig. 1)
cannot be identified. In this study, we investigated pen-
tixafor derivatives with alternative cyclic and acyclic
Fig. 1 Pentixafor-based analogs with different chelators and metals (M, gray). A constitutes the pentapeptide core cyclo(-D-Tyr-N-Me-D-Orn-L-Arg-L-
2-Nal-Gly-) whereas B contains an additional aminomethylbenzoyl (AMB) linker between the peptide and chelator
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chelators and evaluated these ligands in vitro. With re-
gard to the utilized chelators, the following nuclides
relevant for medical purposes have been investigated:
Ga3+, AlF2+, Zr4+, Cu2+, In3+, Lu3+, Y3+, and Bi3+ (Fig. 1).
Methods
General
Trityl chloride polystyrene (TCP) resins were purchased
from PepChem (Tübingen, Germany) and Sigma-Aldrich
(Steinheim, Germany). 9-fluorenylmethyloxycarbonyl (Fmoc)
and all other protected amino acid analogs were ob-
tained from Iris Biotech (Marktredwitz, Germany) or
Bachem (Bubendorf, Switzerland). Chelators were ob-
tained from CheMatech (Dijon, France, or Macrocyclics
(Dallas, USA)) while all other chemicals were bought from
Sigma-Aldrich, Fluka, or Merck (Darmstadt, Germany)
if not stated otherwise. Solvents and all other organic
reagents were purchased from Sigma-Aldrich (Munich,
Germany), CLN (Freising, Germany), and VWR (Darmstadt,
Deutschland). Water for reversed phase (RP)-HPLC
was filtered through a 0.2-μm filter (Thermo Scientific,
Barnstead Smart2Pure, Niederelbert, Germany). Analyt-
ical RP-HPLC was performed on a Nucleosil 100 C18
(5 μm, 125 × 4.0 mm2) column (CS GmbH, Langerwehe,
Germany) using a Sykam gradient HPLC System (Sykam
GmbH, Eresing, Germany). For elution, linear gradients of
acetonitrile (0.1 % (v/v) trifluoroacetic acid (TFA), solvent
B) in water (0.1 % TFA (v/v), solvent A) at a constant flow
of 1 mL/min over 15 min were used. UV detection was
performed at 220 and 254 nm using a 206 PHD UV-vis
detector (LinearTM Instruments Corporation, Reno,
USA). Purities were determined at 220 nm using LabSolu-
tions software by Shimadzu Corp. Preparative RP-HPLC
was performed on a Sykam gradient HPLC System (Sykam
GmbH, Eresing, Germany) equipped with a Multospher
100 RP 18-5 (250 × 20 mm2) column (CS GmbH, Langer-
wehe, Germany) at a constant flow of 10 mL/min using
the same solvents as stated above (duration of gradient,
20 min). Electrospray ionization (ESI)-mass spectra were
recorded on a Varian 500-MS IT mass spectrometer
(Agilent Technologies, Santa Clara, USA).
General SPPS
Peptides were synthesized manually on solid TCP sup-
port using standard Fmoc strategy and an Intelli-Mixer
syringe shaker (Neolab, Heidelberg, Germany). As side
chain protecting groups, N-[1-(4,4-dimethyl-2,6-dioxo-
cyclohexylidene)ethyl] (Dde) for D-Orn and t-butyl and
2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf )
groups for D-Tyr and Arg, respectively, were utilized.
O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium
tetrafluoroborate (TBTU) and N-hydroxybenzotriazole
(HOBt) were used as coupling reagents. N-alkylated amines
were acylated using (1-[bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluoropho-
sphate) (HATU) with 1-hydroxy-7-azabenzotriazole (HOAt)
as racemization suppressant.
Cleavage of the peptide from the TCP support with
retention of acid-labile protection groups was achieved
by treating the peptidyl resin with a solution of dichlo-
romethane (DCM):trifluoroethanol:acetic acid (6:1:3)
(v/v/v); for deprotection of acid-labile groups, TFA:trii-
sopropylsilane (TIPS):H2O (95:2.5:2.5) (v/v/v) was used
(2× 30 min). Deprotection of Dde was carried out with
2 % hydrazine monohydrate in dimethylformamide
(DMF) (v/v).
For Fmoc-deprotection, the peptide was treated with
20 % piperidine in N-methyl-2-pyrrolidone (NMP) (v/v)
for 20 min.
For general coupling of amino acids, a solution of
Fmoc-Xaa-OH (1.5 equiv), TBTU (1.5 equiv), HOBt (1.5
equiv), and N,N-diisopropylethylamine (DIPEA) (5 equiv)
in NMP (1 mL/g resin) was added to the resin-bound pep-
tide and shaken for 90 min at room temperature and
washed six times with NMP.
Synthesis of A
The peptide was synthesized according to a previously
published procedure [12]. In short, synthesis was carried
out using a standard Fmoc strategy using a TCP resin as
solid support and HOBt/TBTU as coupling reagents.
After selective N-methylation of D-Orn, D-Tyr was coupled
to the peptide with HATU/HOAt, cleaved from the resin,
and finally cyclized.
Coupling AMB to the D-Orn side chain was carried
out using Fmoc- or Boc-protected AMB (1.5 equiv).
AMB was preactivated with DIC (N,N′-diisopropyl-car-
bodiimide) (1.5 equiv), HOAt (1.5 equiv), and DIPEA
(4.5 equiv) in 5 mL DMF for 10 min. The D-Orn depro-
tected peptide precursor was dissolved in DMF, and the
preactivated linker was added. After complete reaction
(2 h), Fmoc deprotection and semi-preparative HPLC
purification, appropriate chelators were coupled to the
peptide. HPLC (50 to 100 % B in 15 min): tR = 8.0 min;
ESI-mass spectra (MS): calculated for (C61H78N10O10S):
1142.5; found: m/z = 1143.6 [M+H]+.
Coupling of chelators and metal complexation
A molar excess of the activated chelator was added to a
free amino group of the peptide analog. Subsequent to
successful coupling, the chelator-conjugated peptide was
deprotected and purified. Metal complexation was per-
formed in the presence of weakly chelating acetate
buffers to reduce the likelihood of hydrolysis. Solutions
for metal labeling comprised LuCl3 (20 mM), pH = 6.0;
InCl3 (20 mM), pH = 4.5; and YCl3 (20 mM), pH = 5.9,
each in ammonium acetate (0.1 M) and Ga(NO3)3 (2 mM)
pH= 3.0; Cu(OAc)2 pH = 6.0; and ZrCl4 (20 mM) pH= 1.3,
Poschenrieder et al. EJNMMI Research  (2016) 6:36 Page 3 of 8
each in water. The chelator-conjugated peptide (250 μL,
2 mM, 1 equiv) was dissolved in H2O and DMSO up to
50 % (v/v), if necessary, and the metal (1–10 equiv) was
added, pH adjusted, and heated for 30 min. Final metalated
peptides were obtained in a purity ≥ 95 %, and used for in
vitro studies without further purification, unless stated
otherwise.
Coupling of DOTA or NOTA
For DOTA/NOTA derivatization, 1,4,7,10-tetraazacyclo-
dodecane-1,4,7,10-tetraacetic acid (DOTA) or 1,4,7-tria-
zacyclononane-triacetic acid (NOTA) (1 equiv) was
preactivated for 20 min using N-hydroxysuccinimide
(NHS) (1.25 equiv), 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide (EDCI) (1.25 equiv), and DIPEA (2 equiv)
dissolved in water (1 mL/0.3 mmol). The peptide B (0.25
or 0.3 equiv, for DOTA or NOTA, respectively) was dis-
solved in DMF (1 mL per 0.15 mmol of peptide) and
slowly added to the reaction mixture according to a pre-
viously published protocol [13]. 3: HPLC (30 to 55 % B
in 15 min): tR = 10.1 min; ESI-MS: calculated for
(C56H73N13O12): 1119.6; found: m/z = 1121.0 [M+H]+,
1143.0 [M+Na]+; 1: HPLC (30 to 55 % B in 15 min): tR =
8.8 min; ESI-MS: calculated for (C60H80N14O14):




anhydride) (2 equiv) was dissolved in anhydrous DMF to
obtain a white suspension and added to a solution of B
(1 equiv) and triethylamine (10 equiv) in anhydrous
DMF. 2: HPLC (30 to 55 % B in 15 min): tR = 9.8 min;
ESI-MS: calculated for (C63H84N14O16): 1292.6; found:




(3 equiv) was coupled to B (1 equiv) using a solution of
DIC (2 equiv), HOAt (2 equiv), and DIPEA (6 equiv) in
anhydrous DMF. The product was fully deprotected
and purified. HPLC (30 to 55 % B in 15 min): tR =
10.8 min; ESI-MS: calculated for (C59H77N13O14):




(2 equiv) was coupled to B (1 equiv) using a solution of
DIC (1.5 equiv), HOAt (1.5 equiv), and DIPEA (4.5 equiv)
in anhydrous DMF. After successful coupling, the
product was deprotected and purified. HPLC (30 to
60 % B in 15 min): tR = 8.0 min; ESI-MS: calculated for




acid (p-SCN-Bn-DTPA) (21.0 mg, 32.4 μmol, 1.5 equiv)
was coupled to B (18.0 mg, 21.6 μmol, 1 equiv) with
DIPEA in anhydrous DMF to obtain pH ≈ 9. HPLC (30
to 60 % B in 15 min): tR = 11.2 min; ESI-MS: calculated for
(C66H82N14O17S): 1374.6; found: m/z = 1375.8 [M+H]+.
Coupling of p-SCN-Bn-DFO
p-Isothiocyanatobenzyl-desferoxamine (DFO-Bn-NCS)
(21.0 mg, 32.4 μmol, 1.5 equiv) was coupled to B
(18.0 mg, 21.6 μmol, 1 equiv) in anhydrous DMF
and adjusted with NEt3 to pH = 9.5. HPLC (30 to
60 % B in 15 min): tR = 14.0 min; ESI-MS: calculated




diyl)diacetic acid (NCS-MP-NODA) (1.9 mg, 5.4 μmol,
1.5 equiv) was coupled to A (3 mg, 3.6 μmol, 1 equiv) with
DIPEA (1.1 μL, 3.2 μmol, 2 equiv) in anhydrous DMF to
obtain pH ≈ 9. HPLC (20 to 50 % B in 15 min): tR =
9.0 min; ESI-MS: calculated for (C54H71N13O10S):
1093.5; found: m/z = 1095.1 [M+H]+, 1116.7 [M+Na]+.
Chelation of Ga3+ with DOTA, DOTAGA, NOTA, NODAGA
conjugates
A solution of Ga(NO3)3 (250 μL, 2 mM, 1 equiv) in
water, pH = 3.0, was added to the chelator-conjugated
peptide, (250 μL, 2 mM, 1 equiv) dissolved in H2O and,
if necessary, in DMSO up to 50 % (v/v). The final pH of
the mixture was adjusted to 4–6 and heated at 90 °C for
30 min. [natGa]1: HPLC (30 to 55 % B in 15 min): tR =
9.0 min; ESI-MS: calculated for (C60H78GaN14O14):
1287.5; found: m/z = 1287.7 [M+H]+, 1311.7 [M+Na]+;
[natGa]2: HPLC (30 to 55 % B in 15 min): tR = 9.8 min
(Ga); ESI-MS: calculated for (C63H82GaN14O16):
1359.5; found: m/z = 1361.3 [M+H]+, 1383.2 [M+Na]+;
[natGa]3: HPLC (30 to 55 % B in 15 min): tR = 9.3 min;
ESI-MS: calculated for (C56H71GaN13O12): 1186.5;
found: m/z = 1188.9 [M+H]+, 1209.9 [M+Na]+; [natGa]4:
HPLC (30 to 55 % B in 15 min): tR = 10.8 min; ESI-MS:
calculated for (C59H74GaN13O14): 1257.5; found: m/z =
1258.8 [M+H]+.
Chelation of In3+, Y3+, and Lu3+ with DOTA, DOTAGA, and
DTPA conjugates
A solution of either YCl3, LuCl3, or InCl3 (250 μL, 20 mM,
10 equiv) in ammonium acetate (0.1 M, pH= 6.0) was
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added to the chelator-conjugated peptide (250 μL, 2 mM,
1 equiv). The pH was adjusted to 4–6, and the mixture
heated at 90 °C for 30 min. [natLu]1 and [natY]1: HPLC
(10 to 50 % B in 15 min): tR = 10.7 min each; ESI-MS:
calculated for (C60H77LuN14O14): 1392.5; found: m/z=
1393.8 [M+H]+; ESI-MS: calculated for (C60H77N14O14Y):
1306.5; found: m/z= 1308.5 [M+H]+, 1329.7 [M+Na]+;
[natLu]2 and [natY]2: HPLC (30 to 55 % B in 15 min): tR=
9.8 min each; ESI-MS: calculated for (C63H80LuN14O16):
1463.5; found: m/z = 1465.3 [M+H]+, 1488.1 [M+Na]+;
ESI-MS: calculated for (C63H80N14O16Y): 1377.5;
found: m/z = 1379.3 [M+H]+, 1402.2 [M+Na]+; [natIn]7:
HPLC (30 to 55 % B in 15 min): tR = 10.3 min; ESI-MS:
calculated for (C66H77InN14O17S): 1484.4; found: m/z =
1487.4 [M+H]+; [natLu]6, [natIn]6, and [natY]6: HPLC
(30 to 60 % B in 15 min): tR = 9.1 min each; ESI-MS:
calculated for (C58H71LuN13O16): 1380.5; found: m/z =
1382.8 [M+H]+, for (C58H71N13O16Y): 1294.4; found:
m/z = 1296.7 [M+H]+, for (C58H71InN13O16): 1320.4;
found: m/z = 1322.9, [M+H]+, 1344.9 [M+Na]+.
Chelation of Zr4+ with 8
To obtain [natZr]8, a solution of ZrCl4 in water (pH = 1.3)
(20 mM) was added to the DFO-bearing peptide (2 mM).
Quantitative complexation at room temperature occurred
within a few minutes without forming any side products.
HPLC (30 to 60 % B in 15 min): tR = 14.0 min; ESI-MS:
calculated for (C77H103N18O15S2Zr): 1673.6; found:
m/z = 1674.5 [M+H]+.
Chelation of Bi3+ with DOTA and DOTAGA conjugates
[natBi]1 and [natBi]2 were prepared by the dropwise
addition of natBi(H3CCOO)3 (10 equiv) to a solution of
DOTA or DOTAGA-peptide at pH ~ 5. [natBi]1: HPLC
(30 to 55 % B in 15 min): tR = 8.8 min; ESI-MS: calculated
for (C60H77BiN14O14): 1426.6; found: m/z = 1427.4
[M+H]+, 1451.5 [M+Na]+, 1465.1 [M+K]+; [natBi]2:
HPLC (30 to 55 % B in 15 min): tR = 9.8 min; ESI-MS:
calculated for (C63H80BiN14O16): 1497.6; found: m/z =
1499.3 [M+H]+, 1521.3 [M+Na]+, 1537.3 [M+K]+.
Chelation of Cu2+ with DOTA, DOTAGA, NOTA, NODAGA,
and DTPA conjugates
A solution of Cu(OAc)2 (250 μL, 2 mM, 1 equiv) in
water, pH = 6.0, was added to the chelator-conjugated
peptide, (250 μL, 2 mM, 1 equiv). The mixture was incu-
bated at room temperature for 30 min. HPLC revealed
quantitative complexation. [natCu]1: HPLC (30 to 55 %
B in 15 min): tR = 10.8 min; ESI-MS: calculated for
(C60H77CuN14O14): 1280.5; found: m/z = 1282.8 [M+H]+,
1306.8 [M+Na]+.
[natCu]2: HPLC (30 to 55 % B in 15 min): tR =
11.0 min; ESI-MS: calculated for (C63H82CuN14O16):
1353.5; found: m/z = 1354.8 [M+H]+, 1377.8 [M+Na]+;
[natCu]3: HPLC (30 to 55 % B in 15 min): tR = 10.5 min;
ESI-MS: calculated for (C56H71CuN13O12): 1180.5;
found: m/z = 1181.8 [M+H]+, 1203.6 [M+Na]+; [natCu]4:
HPLC (30 to 55 % B in 15 min): tR = 10.9 min; ESI-MS:
calculated for (C59H74CuN13O14): 1251.5; found:
m/z = 1253.8 [M+H]+; [natCu]6: HPLC (30 to 55 % B
in 15 min): tR = 9.8 min; ESI-MS: calculated for
(C58H72CuN13O16): 1269.5; found: m/z = 1271.7 [M+H]+,
1232.8 [M+Na]+.
Chelation of AlF2+ with NOTA and NODA conjugates
The peptide was labeled with [natF]AlF by mixing AlCl3
(1.2 equiv, 0.468 μmol in 0.5 M NaOAc, pH = 4.0), NaF
(1.2 equiv 0.468 μmol in 0.5 M sodium acetate, pH = 4.0)
with 3 or 5 (1 equiv, 0.39 μmol). The [natF]AlF-labeled
peptide was purified using RP-HPLC on a C18 (5 μm,
125 × 4.0 mm). [natF]AlF-3: HPLC (23 % B in 15 min): tR =
10.5 min; ESI-MS: calculated for (C56H71AlFN13O12):
1163.5; found: m/z = 1164.9 [M+H]+; [natF]AlF-5: HPLC
(20 to 50 % B in 15 min): tR = 8.2 min; ESI-MS: calculated
for (C54H69AlFN13O10S): 1137.5; found: m/z = 1139.0
[M+H]+, 1160.9 [M+Na]+.
Cell culture and determination of CXCR4 receptor affinity
(IC50)
For in vitro experiments, the Jurkat T - cell line was
used. The cells were maintained in RPMI 1640
medium (Biochrom) containing 10 % fetal calf serum
(FCS) (Biochrom). The cell line was cultured at 37 °C
in a humidified atmosphere with 5 % CO2 and pas-
saged two to three times a week, depending on the
cell count.
CXCR4 affinities were determined in competitive
binding assays using Jurkat cells with [125I]FC131 as the
radioligand according to a protocol similar to previously
published [7]. FC131 (cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-
Gly-)) [14] was synthesized and iodinated as described
previously [7]. Jurkat cells (4 × 105 cells per vial) were in-
cubated with the respective peptide of interest at the
final concentrations ranging from 10−11 to 10−5 M and
app. 0.1 nM of [125I]FC131. The total sample volume
was 250 μL. After an incubation time of 120 min, the
vials were centrifuged at 1300 rpm (Heraeus Megafuge,
Thermo) for 3 min and the supernatant was removed.
The cells were washed twice with 200 μL ice-cold Hank’s
balanced salt solution (HBSS). After each washing step,
the samples were centrifuged and the supernatant re-
moved. Finally, the amount of displaced and bound radi-
oligand in the combined fractions of the supernatant
and the cell pellet was quantified. The half maximal in-
hibitory concentration (IC50) values were determined
using GraphPad Prism software.
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Results
Based on the promising results of [68Ga]pentixafor [7–11,
15], the influence of different pentixafor-based peptide-
linker-chelators on the CXCR4 affinity (IC50) has been
evaluated. For this purpose, seven different chelators have
been coupled via an AMB moiety to the D-Orn side chain
of the CPCR4.2 core peptide A (Fig. 1): (a) DOTA, (b)
DOTAGA, (c) NOTA, (d) 1,4,7-triazacyclononane,1-gluta-
ric acid-4,7-acetic acid (NODAGA), (e) DTPA, (f) p-SCN-
Bn-DTPA, (g) p-SCN-Bn-Desferrioxamine (DFO), and (h)
p-SCN-Bn-NODA, whereby SCN-Bn-NODA was directly
coupled to the pentapeptide core without ABS. Depending
on the preferred metals for each chelator, reference Ga3+,
complexes with AlF2+, Zr4+, Cu2+, In3+, Lu3+, Y3+, and Bi3+
were prepared and evaluated in competitive binding assays
on Jurkat T - cells with [125I]FC131 as the radioactive ref-
erence (Table 1).
As already demonstrated [7, 8], non-metalated pentix-
afor (1) shows low affinity (IC50: 102 ± 17 nM) towards
CXCR4, whereas the Lu3+ and Y3+ complexes (IC50:
40.9 ± 12 and 40.8 ± 27 nM, respectively) exhibit affin-
ities quite similar to [natIn]pentixafor (IC50: 44 ± 4 nM)
[7]. Surprisingly, the affinity of the Bi3+ complex is even
higher (IC50: 22.1 ± 7.0 nM) than the affinity of [
natGa]-
pentixafor (IC50: 24.6 ± 2.5 nM) thus making [
213Bi]pen-
tixafor an attractive α-particle emitting therapeutic
analog for endoradiotherapy. The affinity of the corre-
sponding Cu2+ complex was low (131 ± 11 nM). With
regard to previous reports [7], it is important to notice
that absolute IC50 values for [
natGa]pentixafor differ be-
cause higher cell numbers were used for the IC50 experi-
ments in this study (4 × 105 vs 2 × 105 cells/sample).
When switching to the corresponding DOTAGA de-
rivatives, the IC50 values indicate a similar order within
the series of investigated metal complexes with generally
lower affinities (Table 1), except the Bi3+-complex, which,
again surprisingly, showed only a small decrease of CXCR4
affinity. Thus, with respect to receptor affinity, DOTAGA-
pentixafor was found to offer no advantage over DOTA-
pentixafor analogs.
A corresponding evaluation of the NOTA and NODAGA
derivatives identified [natGa3+]3 as the ligand with the high-
est affinity in this study (IC50: 17.8 ± 7.7 nM). All other
complexes, including the [natF]AlF-NOTA derivative, seem
to be unsuitable for further preclinical evaluation or poten-
tial clinical application. Similar disappointing results were
obtained for NODA-Bn-SCN, DTPA, DTPA-Bn-SCN, and
DFO-BN-SCN derivatives.
Discussion
Experiences in the development of CXCR4-targeting
peptides showed that affinities to the CXCR4 receptor
can be significantly affected by even moderate structural
modifications in the pentapeptide core [16–19], the
linker unit [20], or the chelate [7, 8]. This is in contrast
to previous experiences of GPCR, glycoprotein, or enzyme-
targeting peptides, such as SSTRs, GRPRs (bombesin), and
integrins (e.g., αvß3, RGD peptides), as well as the prostate-
specific membrane antigen (PSMA), to mention only a
few. A variety of peptides towards these targets have
been developed and—unlike CXCR4—conjugated with
a broad spectrum of linker/chelator moieties. For αvß3-
binding RGD peptides, the Lys side chain of the typic-
ally used c(Arg-Gly-Asp-D-Phe-Lys) does not influence
the binding of the peptide in the cleft between the two
αv and β3 subunits that forms the heterodimeric trans-
membrane glycoprotein [21]. Thus, these RGD peptides
tolerate the introduction of spacers and chelator or the
formation of multimers, such as dimers, tetramers, and
octamers [22, 23]. Similar freedom of variation, although
not that multifarious, has been found for SST ligands.
Tyr3-octreotate for instance was conjugated to both DTPA
and DOTA and labeled with natIn, natGa, or natY. All con-
jugates, including metal-free octreotate bound hSST2 with
high affinity (0.2 to 3.9 nM), regardless of the chelator and
metal used [24]. This was confirmed by other SST2 bind-
ing peptides, coupled to NODAGA, CB-TE2A, or DOTA
and labeled with natGa or natCu resulting in affinities in a
range from 1.3 to 12.5 nM [25]. Moreover, modification of
Tyr3-octreotate by glucose or cellobiose and 4-[18F]fluoro-
benzaldehyde or 2-fluoropropionic acid resulted in almost
unchanged SST2 affinities in the range of 1.3 to 3.1 nM
Table 1 IC50 values of different metal-chelate conjugates con-
sisting of cyclo(-D-Tyr-N-Me-D-Orn(spacer-[M3+]chelator)-L-Arg-L-2-
Nal-Gly-), expressed as mean ± SD (n = 3)
Compound IC50/nM Compound IC50/nM
1 (DOTA) 102 ± 17 2 (DOTAGA) 654 ± 263
[natGa3+]1 24.8 ± 2.5 [natGa3+]2 380 ± 102
[natBi3+]1 22.1 ± 7.0 [natBi3+]2 29.4 ± 7.6
[natCu2+]1 131 ± 11 [natCu2+]2 1165 ± 220
[natLu3+]1 40.9 ± 12 [natLu3+]2 188 ± 2.8
[natY3+]1 40.8 ± 27 [natY3+]2 126 ± 89
3 (NOTA) 253 ± 49 4 (NODAGA) 275 ± 106
[natGa3+]3 17.8 ± 7.7 [natGa3+]4 342 ± 72
[natCu2+]3 46.1 ± 26 [natCu2+]4 343 ± 10
[natF]AlF-3 220 ± 57
5 (SCN-Bn-NODA) 115 ± 24 6 (DTPA) 53 ± 7.9
[natF]AlF-5 329 ± 49 [natY3+]6 156 ± 6.7
7 (SCN-Bn-DTPA) 200 ± 73 [natLu3+]6 111 ± 77
[natIn3+]7 74.1 ± 2.4 [natIn3+]6 90 ± 42
8 (SCN-Bn-DFO) 105 ± 35 [natCu2+]6 175 ± 66
[natZr4+]8 148 ± 27
FC131 as control 9.9 ± 2.4 nM
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[26]. Hence, compared to CXCR4-binding pentixafor
derivatives, where discrepancies varied from 17.6 to
1165 nM (Ga-NOTA and Cu-DOTAGA conjugated to
the same highly affine scaffold of CPCR4.2), the effect
of chelator and metal exchange was much less pronounced.
Profound investigations on bombesin-receptor medi-
ated imaging agents have shown that bombesin analogs
can be conjugated and labeled with a broad range of
chelators and metals under retention of their receptor
affinity [27]. Smith et al. listed 12 bombesin conjugates,
labeled with a variety of metal chelation systems, all of
them with an unchanged affinity in the range of 0.5 to
10.5 nM [28, 29].
Regarding PSMA, 14 99mTc-based imaging agents and
five copper compounds were investigated with various
common chelators of 99mTc and 64Cu, resulting in high
affinity for every compound with Ki values ranging from
0.03 to 16.3 nM [30] and 0.19 to 13.26 nM [31] for Tc
and Cu compounds, respectively. Free, Ga3+-, and Lu3
+-labeled PSMA DOTA and DOTAGA conjugates were
shown to be highly specific as well, ranging from 10.2 to
54.7 nM [32]. This list can be prolonged with 18F-tracers
developed by Pomper et al. [33, 34] and other further
68Ga-tracers developed by Eder et al. [35, 36].
Although different groups used different models for
affinity evaluation, the relative trend shows that, in
contrast to the examples above, the CXCR4 affinity is
strongly influenced by the entire ligand-spacer-chelator-
radiometal construct. During the development of linker-
bridged dimers, Demmer et al. could demonstrate that even
dimers, consisting of one high affinity and one “non-”
CXCR4-binding peptide exhibit higher affinity when com-
pared with the high affinity monomer conjugated with the
used linker [20]. The authors conclude a subsite binding of
the second peptide unit close to the main binding pocket.
Based on the results of this study, we conclude that binding
of the AMB-[M3+]chelator moiety of [natGa]pentixafor and
[natGa3+]3 significantly contributes to and is a prerequisite
for high affinity binding of the entire peptide ligand. Conse-
quently, depending on the chelator, metalation can have a
significant effect on the affinity towards CXCR4.
Conclusions
In summary, these studies demonstrated that pentixafor,
consisting of the cyclic peptide cyclo(-D-Tyr-N-Me-D-
Orn-L-Arg-L-2-Nal-Gly-) and conjugated at the Orn side
chain with AMB-[natGa]DOTA, represents a highly opti-
mized ligand. As a result of this study, two further ligands,
a Ga-NOTA ([natGa3+]3) and a Bi-DOTA ([natBi3+]1) de-
rivative with slightly higher affinity to hCXCR4, have been
developed. Whereas the Ga3+-ligand [natGa3+]3 suffers
from a lower hydrophilicity and thus presumably inferior
pharmacokinetics compared to [natGa]pentixafor, the
Bi3+-complex is expected to be a very promising new
ligand for further studies towards α-emitter-based
endoradiotherapeutic approaches, including multiple mye-
loma and other lymphoproliferative disorders.
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